Account

Sign in to access your account and subscription

The FDA's New Guidelines on Financial Disclosure by Clinical Investigators

The FDA has recently updated its Guidance for Industry: Financial Disclosure of Clinical Investigators for the first time since 2001. This article briefly examines the key changes and their practical implications in product liability cases.

20 minute read January 31, 2012 at 08:10 AM
By
Christiana C. Jacxsens And Jessica C. Cabral
The FDA's New Guidelines on Financial Disclosure by Clinical Investigators

There has been a growing number of claims in medical device and pharmaceutical product liability actions based on purported conflicts of interest of clinical investigators conducting medical device or pharmaceutical clinical studies.

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The Copyright Royalty Board (CRB), which works under the umbrella of the Librarian of Congress, sets statutory-license royalty terms and rates. The U.S. Courts of Appeals for the D.C. Circuit recently issued two notable decisions about the CRB.

October 01, 2026